Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States

Chest

Volumn 151, Issue 6, 2017, Pages 1320-1328

  Ramos, Kathleen J ^a   Quon, Bradley S ^e   Heltshe, Sonya L ^b,c   Mayer Hamblett, Nicole ^b,c,d   Lease, Erika D ^a   Aitken, Moira L ^a   Weiss, Noel S ^d   Goss, Christopher H ^a,b,c  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

cystic fibrosis; FEV1; lung function; lung transplantation; survival

Indexed keywords

INSULIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERIAL COLONIZATION; BODY MASS; BURKHOLDERIA CEPACIA; BURKHOLDERIA CEPACIA INFECTION; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; EDUCATION; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC HETEROGENEITY; HEMOPTYSIS; HETEROZYGOSITY; HIGH SCHOOL GRADUATE; HOMOZYGOSITY; HUMAN; INCIDENCE; KIDNEY FAILURE; LIFE EXPECTANCY; LIVER CIRRHOSIS; LUNG FIBROSIS; LUNG FUNCTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MEDICAID; OSTEOPOROSIS; OXYGEN THERAPY; PANCREATIC INSUFFICIENCY; PNEUMOTHORAX; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPUTUM CULTURE; SURVIVAL RATE; SURVIVAL TIME; TRANSPLANTATION FREE SURVIVAL; UNITED STATES; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; DISEASE COURSE; LUNG; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PSEUDOMONAS INFECTIONS; SEX DIFFERENCE; YOUNG ADULT;

ADULT; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; COHORT STUDIES; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LUNG; LUNG TRANSPLANTATION; MALE; OXYGEN INHALATION THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 85020874979     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.01.019     Document Type: Article

References (18)

1. O'Sullivan, B.P., Freedman, S.D., Cystic fibrosis. Lancet 373:9678 (2009), 1891–1904.
2. Cystic Fibrosis Foundation Patient Registry, 2014 Annual Data Report. Bethesda, Maryland, Cystic Fibrosis Foundation, 2015.
3. Weill, D., Benden, C., Corris, P.A., et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 34:1 (2015), 1–15.
4. Kerem, E., Reisman, J., Corey, M., Canny, G.J., Levison, H., Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326:18 (1992), 1187–1191.
5. Milla, C.E., Warwick, W.J., Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 113:5 (1998), 1230–1234.
6. Yusen, R.D., Edwards, L.B., Kucheryavaya, A.Y., et al. The registry of the International Society for Heart and Lung Transplantation: thirty-third adult lung and heart-lung transplantation report—2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant 35:10 (2016), 1170–1184.
7. George, P.M., Banya, W., Pareek, N., et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ, 342, 2011, d1008.
8. Rosenfeld, M., Davis, R., FitzSimmons, S., Pepe, M., Ramsey, B., Gender gap in cystic fibrosis mortality. Am J Epidemiol 145:9 (1997), 794–803.
9. Liou, T.G., Adler, F.R., FitzSimmons, S.C., Cahill, B.C., Hibbs, J.R., Marshall, B.C., Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 153:4 (2001), 345–352.
10. O'Connor, G.T., Quinton, H.B., Kahn, R., et al. Case-mix adjustment for evaluation of mortality in cystic fibrosis. Pediatr Pulmonol 33:2 (2002), 99–105.
11. Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., Gibson, R.L., Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:2 (2002), 91–100.
12. Mayer-Hamblett, N., Rosenfeld, M., Emerson, J., Goss, C.H., Aitken, M.L., Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 166:12 (2002), 1550–1555.
13. Jones, A., Dodd, M., Govan, J., et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 59:11 (2004), 948–951.
14. Knapp, E.A., Fink, A.K., Goss, C.H., et al. The Cystic Fibrosis Foundation Patient Registry: design and methods of a national observational disease registry. Ann Am Thorac Soc 13:7 (2016), 1173–1179.
15. Grambsch, P.M., Therneau, T.M., Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:3 (1994), 515–526.
16. Orens, J.B., Estenne, M., Arcasoy, S., et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25:7 (2006), 745–755.
17. MacKenzie, T., Gifford, A.H., Sabadosa, K.A., et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med 161:4 (2014), 233–241.
18. Stephenson, A.L., Tom, M., Berthiaume, Y., et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J 45:3 (2015), 670–679.